Bictegravir
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='98/989308/Cv/1'> | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='98/989308/Cv/1'> | ||
Bictegravir (INN; BIC, formerly known as GS-9883) is a second-generation integrase inhibitor (INSTI) class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences. See also [https://en.wikipedia.org/wiki/Bictegravir Bictegravir]. | Bictegravir (INN; BIC, formerly known as GS-9883) is a second-generation integrase inhibitor (INSTI) class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences. See also [https://en.wikipedia.org/wiki/Bictegravir Bictegravir]. | ||
| + | |||
| + | In 2016, bictegravir was in a Phase 3 trial as part of a single tablet regimen in combination with tenofovir alafenamide (TAF) and emtricitabine (FTC) for the treatment of HIV-1 infection[5] and the combination drug bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) was approved for use in the United States in 2018.[6] | ||
<scene name='98/989308/Overall/2'>Structure of the STLV intasome:B56 complex bound to the strand-transfer inhibitor bictegravir</scene> ([[7ouh]]). | <scene name='98/989308/Overall/2'>Structure of the STLV intasome:B56 complex bound to the strand-transfer inhibitor bictegravir</scene> ([[7ouh]]). | ||
Revision as of 12:16, 28 August 2023
| |||||||||||
